JAK1 and hepatocellular carcinoma: In contrast, the administration of ruxolitinib, a selective JAK1/2 inhibitor, destabilized PD-L1 and improved the therapeutic efficacy of anti-Tim-3 immune checkpoint therapy in HCC [44].